Molecule profile · Module 7
KPV — evidence and research limits
MOLECULE PROFILE
- Evidence summary
- Preclinical evidence
- Dalmasso and colleagues studied KPV transport and inflammatory responses in cells and mouse colitis models. These findings support a mechanistic research question; they are not a human efficacy trial and do not establish a clinical administration route or regimen. The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
- Regulatory status varies by jurisdiction
- The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Identity and mechanism
KPV denotes lysine-proline-valine, a tripeptide related to the terminal sequence of alpha-melanocyte-stimulating hormone. The course discusses peptide transport through PepT1 and inflammatory responses in cell and mouse models. These studies address experimental transport and inflammation, not an established treatment schedule for human intestinal disease.
What the evidence supports
Dalmasso and colleagues studied KPV transport and inflammatory responses in cells and mouse colitis models. These findings support a mechanistic research question; they are not a human efficacy trial and do not establish a clinical administration route or regimen.
The interpretation is specific to the studied molecule, formulation, route, population, and endpoint. Reported commercial regimens are not validated by a study of a different product or outcome.
Regulatory context
The academic source does not establish a current authorization for every preparation sold under this name. Product identity, formulation, indication, jurisdiction, and current official labeling must be checked separately. A discussion of compounding or an advisory meeting is not a product approval.
Safety and uncertainty
Cellular and murine data do not establish human safety for a proposed administration route. Human safety cannot be inferred from a cell result, a product name, or lack of events in a small report. These educational adaptations do not provide an administration protocol.
Continue learning
Explore Module 7 in PEPTIDE Academy for the full evidence discussion.
Reported practice and its limits
A conference report can describe what a practitioner observed without showing how often a treatment works. Read the report with a structured record: source and date, product identity, formulation, route, reported exposure, follow-up, concurrent interventions and measured outcome. Mark missing information as unknown. A sequence of several interventions does not identify which caused a change.
For this profile, conference material is a source of questions, not an additional efficacy trial. A treatment table without a denominator cannot establish how common a practice is. An amount stated only in syringe units cannot establish a mass without the relevant concentration. Do not complete missing concentrations or reconstruct a regimen. Any future case example should be synthetic and clearly labeled; the underlying clinical claim still needs independent evidence.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. DOI: 10.1053/j.gastro.2007.10.026. PMID: 18061177.DOI 10.1053/j.gastro.2007.10.026 · PMID 18061177
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. DOI: 10.1002/ibd.20334. PMID: 18092346.DOI 10.1002/ibd.20334 · PMID 18092346
Related resources
Molecule profile · Module 7
LL-37
LL-37 is a human cathelicidin peptide with antimicrobial and immunological roles. Its activity depends on tissue, concentration, and biological context; antimicrobial activity is not a blanket clinical benefit. The human wound studies discussed in the course used topical preparations for venous ulcers, a different intervention from an unspecified systemic preparation.
Molecule profile · Module 7
Thymosin alpha-1
Thymosin alpha-1 has been investigated as an immunomodulatory peptide in specific disease settings. Immune signaling is a regulated network rather than a single defense switch. A favorable biomarker response cannot stand in for improved survival, and evidence from one infection or population does not define a general immune-enhancement indication.
Molecule profile · Module 3
AOD-9604
AOD-9604 is a modified fragment related to the C-terminal region of growth hormone. The rationale discussed in the course concerns metabolic effects attributed to the fragment, rather than assuming that it reproduces every action of full-length growth hormone. Identity, formulation, and route must be specified when comparing reports.